- Home
- Equipment
- usa california
- pre clinical testing
Refine by
Pre Clinical Testing Equipment Supplied In Usa California
27 equipment items found
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CX-188 is our wholly owned PD-1-targeting Probody therapeutic. As with anti-PD-L1 therapies, PD-1 monotherapy and combinations have been associated with significant toxicities. Our preclinical studies have shown that CX-188 has the potential for an improved therapeutic index relative to PD-1 antibodies. The IND for CX-188 was cleared by the FDA. Following a program and portfolio prioritization, ...
by:Sorrento Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell receptor (TCR) alpha chain constant region (TRAC). In this manner, TRAC is knocked out and antigen is knocked into its locus. The Dimeric Antigen Receptor (DAR) utilizes a Fab instead of the scFv ...
by:Hillhurst Biopharmaceuticals, Inc. based inSan Diego, CALIFORNIA (USA)
Therapeutic medical gases have the potential to address a wide spectrum of diseases, but have been limited by inhaled delivery, which for conscious patients is inaccurate in dosing, potentially unsafe, and highly intrusive. Hillhurst’s GLASS technology platform is designed to address the challenges of inhaled gases by enabling liquid delivery of therapeutic gases to ensure accurate dosing ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX is developing CX-2009, a Probody drug conjugate (PDC) conjugated with DM4, a highly potent cytotoxic drug, targeting CD166, also known as ALCAM. CD166 is a molecule widely and highly expressed on solid tumor cells and previously considered “undruggable” given its expression on normal tissues. In preclinical studies, Probody drug conjugates targeting CD166, have led to ...
Manufactured by:Eclipse Regenesis based inMenlo Park, CALIFORNIA (USA)
The Eclipse XL1 is an entirely mechanical and repeatable approach designed to grow healthy intestinal tissue 2-3x longer within 2-3 weeks. Early studies have shown that new tissue has begun to function and absorb nutrients equally (or greater) than existing healthy intestinal ...
Manufactured by:Capricor Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Our core therapeutic technology (CAP-1002) is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor’s scientific founder, Dr. Eduardo Marbán. Since the initial publication in 2007, CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to ...
Manufactured by:Xenco Medical based inSan Diego, CALIFORNIA (USA)
The Sorrento™ Bone Graft Substitute is a robust, resorbable bone void filler to fill voids or gaps of the skeletal system in the extremities and pelvis not intrinsic to the stability of the bony structure. Pre-clinical animal studies have revealed its tremendous performance through early osteoblast activity and osteocyte formation with little fibrotic tissue. Sorrento™ Bone Graft ...
by:Cytori Therapeutics Inc. based inSan Diego, CALIFORNIA (USA)
Cytori is developing cell therapies that harness the unique attributes of living cells that are present in an adult human patient’s own adipose (fat) tissue, also known as Adipose-Derived Regenerative Cells ...
Manufactured by:ClearPoint Neuro, Inc. based inIrvine, CALIFORNIA (USA)
The SmartFlow MR Compatible Ventricular Cannula has received 510(k) clearance from the FDA for use in the US for the aspiration of CSF, or injection of the chemotherapy drug Cytarabine into the ventricle. It has also been CE marked for use in Europe for the delivery of approved fluids into the brain or aspiration of CSF. It’s being utilized in approved clinical and preclinical studies for ...
Manufactured by:Galvanize Therapeutics, Inc. based inRedwood City, CALIFORNIA (USA)
The Aliya PEF System is designed for the surgical ablation of soft tissues by delivering high voltage, short duration electrical energy. This targeted electrical energy alters the transmembrane potential, leading to the disruption of cellular homeostasis and inducing non-thermal programmed cell death. Utilizing technologies such as the Aliya Needle and the INUMI™ Flex Needle, the system ...
Manufactured by:Fibralign Corporation based inUnion City, CALIFORNIA (USA)
Fibralign is developing a pipeline of compelling novel products which are based on its proprietary Nanoweave® scaffolding platform that can be tailored to address a wide range of high-value applications. Nanoweave technology provides the means to precisely print 3D scaffolding in such a way that mimics human tissue nano structure and directly influence the body’s repair ...
Manufactured by:Actym Therapeutics based inBerkeley, CALIFORNIA (USA)
Actym Therapeutics, based in Berkeley, CA, is a privately held biotechnology company focused on the discovery and development of novel immunotherapies to treat cancer. The company has developed an attenuated, microbial-based, technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid tumors and not in ...
Manufactured by:Galvanize Therapeutics, Inc. based inRedwood City, CALIFORNIA (USA)
The Aliya PEF System is an advanced medical device used primarily for the surgical ablation of soft tissues, delivering high voltage, short-duration electrical energy to target cells. The system employs pulsed electric field technology to disrupt cellular homeostasis, leading to non-thermal programmed cell death while maintaining the integrity of the surrounding extracellular matrix. The system ...
Manufactured by:Biocardia, Inc. based inSunnyvale, CALIFORNIA (USA)
Leading physicians have described the current Helix Biotherapeutic Delivery System as elegant in its simplicity. BioCardia’s Helix Biotherapeutic Delivery System is the leading percutaneous catheter delivery system for cardiovascular regenerative medicine. It enables local delivery of cell and gene based therapies to treat heart failure, myocardial infarction, ischemia, and cardiac ...
Manufactured by:CeloNova BioSciences, Inc. based inCarlsbad, CALIFORNIA (USA)
CeloNova develops and manufactures novel surface coated technologies including its proprietary Polyzene-F nanocoating and COBRA SG Drug-Coated PTCA Balloon technology. This next-generation innovation is transforming clinical practice and promoting positive outcomes in patients around the ...
Manufactured by:Siolta Therapeutics based inSan Carlos, CALIFORNIA (USA)
The Power to Prevent: Allergic diseases, including atopic dermatitis, food allergy, allergic asthma, and allergic rhinitis, have a common underlying inflammatory cascade and often occur in a sequential order referred to as “the atopic march.” STMC-103H, also known as adored: allergic disease onset prevention study, is Siolta’s proof of concept study aimed at stopping allergic ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
QN-247, formerly referred to as ALAN (Aptamer Linked Anti Nucleolin), is an aptamer-based investigational drug candidate currently under development and evaluation with the potential to treat a variety of different cancer types, including liquid and solid tumors. A key component of this drug candidate, the QN-165 aptamer, has been tested in over 100 cancer patients and is well tolerated with no ...
Manufactured by:Ibio, Inc. based inBryan, TEXAS (USA)
Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid tumors, significant challenges remain. This is in part due to dynamics in the tumor microenvironment, wherein regulatory T cells [Tregs] proliferate and suppress the ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
T cells engineered with chimeric antigen receptors (CARs) have shown exceptional promise as a potentially curative therapy for patients with certain hematologic malignancies. While most researchers and clinical investigators continue to focus on the development of autologous or allogeneic CAR T-cell therapies, we are developing CAR NK cell product candidates created from clonal master engineered ...
Manufactured by:Immune-Onc Therapeutics, Inc. based inPalo Alto, CALIFORNIA (USA)
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia ...